Fosifloxuridine nafalbenamide (Synonyms: NUC-3373)

Name: Fosifloxuridine nafalbenamide
Brand: MedChemExpress
SKU: HY-109115
Rating: 4.5 (1 reviews)

Cat. No.: HY-109115 Purity: 96.05%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunoresearch.

For research use only. We do not sell to patients.

Fosifloxuridine nafalbenamide Chemical Structure

CAS No. : 1332837-31-6

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 270	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 270	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 200	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 280	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 500	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 700	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 980	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Fosifloxuridine nafalbenamide

•Sci Data. 2024 Sep 19.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	0.05 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.068 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.13 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.26 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.31 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.6 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting	[PMID: 21892829]
HeLa	IC₅₀	0.065 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against human HeLa cells after 72 hrs by cell counting Cytostatic activity against human HeLa cells after 72 hrs by cell counting	[PMID: 21892829]
HeLa	IC₅₀	2.5 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting	[PMID: 21892829]
L1210	IC₅₀	0.025 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting	[PMID: 21892829]
L1210	IC₅₀	0.045 μM Compound: 7m, diastereomeric mixture	Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting	[PMID: 21892829]

In Vitro

Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

613.53

Formula

C₂₉H₂₉FN₃O₉P

CAS No.

1332837-31-6

Appearance

Solid

Color

White to off-white

SMILES

O=P(OC[C@H]1O[C@@H](N(C=C(F)C2=O)C(N2)=O)C[C@@H]1O)(N[C@@H](C)C(OCC3=CC=CC=C3)=O)OC4=CC=CC5=C4C=CC=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (162.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6299 mL	8.1496 mL	16.2991 mL
5 mM	0.3260 mL	1.6299 mL	3.2598 mL
10 mM	0.1630 mL	0.8150 mL	1.6299 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 96.05%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (256 KB) HNMR (177 KB) RP-HPLC (247 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.

[2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6299 mL	8.1496 mL	16.2991 mL	40.7478 mL
	5 mM	0.3260 mL	1.6299 mL	3.2598 mL	8.1496 mL
	10 mM	0.1630 mL	0.8150 mL	1.6299 mL	4.0748 mL
	15 mM	0.1087 mL	0.5433 mL	1.0866 mL	2.7165 mL
	20 mM	0.0815 mL	0.4075 mL	0.8150 mL	2.0374 mL
	25 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6299 mL
	30 mM	0.0543 mL	0.2717 mL	0.5433 mL	1.3583 mL
	40 mM	0.0407 mL	0.2037 mL	0.4075 mL	1.0187 mL
	50 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8150 mL
	60 mM	0.0272 mL	0.1358 mL	0.2717 mL	0.6791 mL
	80 mM	0.0204 mL	0.1019 mL	0.2037 mL	0.5093 mL
	100 mM	0.0163 mL	0.0815 mL	0.1630 mL	0.4075 mL

Fosifloxuridine nafalbenamide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fosifloxuridine nafalbenamide1332837-31-6NUC-3373NUC3373NUC 3373Thymidylate SynthasefluorodeoxyuridinemonophosphateFdUMP5-fluorouracil5-FU5-fluorodeoxyuridineFUDRanti-cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Fosifloxuridine nafalbenamide (Synonyms: NUC-3373)

Customer Review

Fosifloxuridine nafalbenamide Related Antibodies

1 Publications Citing Use of MCE Fosifloxuridine nafalbenamide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Fosifloxuridine nafalbenamide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fosifloxuridine nafalbenamide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report